Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis
ObjectiveThe main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) .MethodInclusion criteria: (1) ad...
Saved in:
| Published in | Thorax Vol. 76; no. 10; pp. 1020 - 1031 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BMJ Publishing Group Ltd and British Thoracic Society
01.10.2021
BMJ Publishing Group LTD |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | ObjectiveThe main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) .MethodInclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish. Exclusion criteria: (1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format. Data sources: Medline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane’s tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation. Statistical analyses: frequentist method performed with the ‘netmeta’ library, R package.Results27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. For cure, two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). For mortality, three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate.ConclusionFor cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692). |
|---|---|
| AbstractList | ObjectiveThe main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) .MethodInclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish. Exclusion criteria: (1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format. Data sources: Medline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane’s tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation. Statistical analyses: frequentist method performed with the ‘netmeta’ library, R package.Results27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. For cure, two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). For mortality, three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate.ConclusionFor cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692). The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) .OBJECTIVEThe main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) .Inclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish.METHODInclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish.(1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format.EXCLUSION CRITERIA(1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format.Medline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane's tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation.DATA SOURCESMedline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane's tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation.frequentist method performed with the 'netmeta' library, R package.STATISTICAL ANALYSESfrequentist method performed with the 'netmeta' library, R package.27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. For cure, two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). For mortality, three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate.RESULTS27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. For cure, two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). For mortality, three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate.For cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692).CONCLUSIONFor cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692). The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) . Inclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish. (1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format. Medline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane's tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation. frequentist method performed with the 'netmeta' library, R package. 27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate. For cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692). |
| Author | Blanco-Schweizer, Pablo Martin-Saborido, Carlos Blanco, Jesús Montes-Andujar, Lara Tinoco, Elena Menéndez, Justo Zurdo, Carmen Baez-Pravia, Orville Suarez del Villar, Rafael Torres, Antoni Villanueva, Julio Angel, Verónica Ortiz, Guillermo Segura, Carmen Valero, José Varona, Olga Prol Silva, Estefania Reyes, Vivivan Rodriguez Cobo, Ana Cardinal-Fernández, Pablo A |
| Author_xml | – sequence: 1 givenname: Lara surname: Montes-Andujar fullname: Montes-Andujar, Lara organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 2 givenname: Elena surname: Tinoco fullname: Tinoco, Elena organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 3 givenname: Orville surname: Baez-Pravia fullname: Baez-Pravia, Orville organization: Intensive Care Unit, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 4 givenname: Carlos surname: Martin-Saborido fullname: Martin-Saborido, Carlos organization: Centro de educación superior Hygiea, UDIMA, Madrid, Spain – sequence: 5 givenname: Pablo surname: Blanco-Schweizer fullname: Blanco-Schweizer, Pablo organization: Intensive Care Unit, Rio Hortega University Hospital, Valladolid, Castilla y León, Spain – sequence: 6 givenname: Carmen surname: Segura fullname: Segura, Carmen organization: Intensive Care Unit, Rio Hortega University Hospital, Valladolid, Castilla y León, Spain – sequence: 7 givenname: Estefania surname: Prol Silva fullname: Prol Silva, Estefania organization: Intensive Care Unit, Rio Hortega University Hospital, Valladolid, Castilla y León, Spain – sequence: 8 givenname: Vivivan surname: Reyes fullname: Reyes, Vivivan organization: Intensive Care Unit, Universidad del Bosque, Bogota, Colombia – sequence: 9 givenname: Ana surname: Rodriguez Cobo fullname: Rodriguez Cobo, Ana organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 10 givenname: Carmen surname: Zurdo fullname: Zurdo, Carmen organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Madrid, Spain – sequence: 11 givenname: Verónica surname: Angel fullname: Angel, Verónica organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 12 givenname: Olga surname: Varona fullname: Varona, Olga organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 13 givenname: José surname: Valero fullname: Valero, José organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 14 givenname: Rafael surname: Suarez del Villar fullname: Suarez del Villar, Rafael organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 15 givenname: Guillermo surname: Ortiz fullname: Ortiz, Guillermo organization: Universidad El Bosque, Bogota, Colombia – sequence: 16 givenname: Julio surname: Villanueva fullname: Villanueva, Julio organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 17 givenname: Justo surname: Menéndez fullname: Menéndez, Justo organization: Emergency Department, Hospital Universitario HM Sanchinarro, Madrid, Spain – sequence: 18 givenname: Jesús surname: Blanco fullname: Blanco, Jesús organization: Biomedical Research Center Network for Respiratory Diseases (CIBERES), ISCIII, Madrid, Spain – sequence: 19 givenname: Antoni surname: Torres fullname: Torres, Antoni organization: Biomedical Research Center Network for Respiratory Diseases (CIBERES), Madrid, Spain – sequence: 20 givenname: Pablo A orcidid: 0000-0002-4459-8919 surname: Cardinal-Fernández fullname: Cardinal-Fernández, Pablo A email: pablocardinal@hotmail.com organization: Intensive Care Unit, Hospital Universitario HM Sanchinarro, Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33723019$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1v1DAQhi1URLeFnwCyxIVLwN-J4YSq8iFV4gLnaJw4wktsp7bTZf89Xm1ZpB6Ak63R84zH816gsxCDReg5Ja8p5epN-R4T_NyGuWGE6oZRQaR4hDZUqK7hTKsztCFEkEbxVp2ji5y3hJCO0vYJOue8ZbxqG7S79otLbsAQijMuFjdkPMWEh-j9GlzZNzDcri7ZES_Brj4GB9gFDOM6F7xAcTaU_BYDzvtcrK-FASd75-yu9hxrPdiyi-kH9rZAAwHmfXb5KXo8wZzts_vzEn37cP316lNz8-Xj56v3N40RjJQGOskmwwRIRaUSILiRoGRbb0LIUTJJR2V1p4C0Lacd1dQaNk6TJloabfglenXsu6R4u9pceu_yYOcZgo1r7pkktBOaS13Rlw_QbVxTnfdAtbwlbdfRSr24p1bj7dgvyXlI-_73Sisgj8CQYs7JTieEkv4QXX-Krj9E1x-jq967B97gSt1mDCWBm_9pk6Nt_Pa_H6R_lNNX_-78AsnuwrQ |
| CitedBy_id | crossref_primary_10_3390_metabo12111058 crossref_primary_10_15406_jlprr_2024_11_00312 crossref_primary_10_3390_diagnostics13111869 crossref_primary_10_1016_j_ijantimicag_2023_106905 crossref_primary_10_1371_journal_pone_0298425 crossref_primary_10_1080_14737167_2022_2020649 crossref_primary_10_1136_bmjopen_2022_061023 crossref_primary_10_1007_s11606_024_08674_1 crossref_primary_10_3390_metabo14040195 |
| Cites_doi | 10.1007/s40265-016-0654-4 10.1016/j.ijantimicag.2019.05.023 10.1164/rccm.201908-1581ST 10.1179/joc.2005.17.6.636 10.1111/j.1469-0691.2011.03672.x 10.1136/thx.2009.129502 10.23736/S0375-9393.19.13267-1 10.1186/1471-2466-9-44 10.1002/jrsm.57 10.1186/s12874-015-0060-8 10.1001/archinte.164.5.502 10.1016/S1473-3099(14)71018-7 10.1001/jama.2010.757 10.2165/00151829-200403050-00006 10.1093/jac/dki480 10.1179/joc.2002.14.6.609 10.1016/S0149-2918(02)80078-9 10.1056/NEJMoa1500245 10.1371/journal.pone.0115065 10.1002/jrsm.1044 10.1016/j.jclinepi.2017.10.005 10.1016/S0149-2918(02)80034-0 10.1086/587519 10.1016/S0924-8579(00)00344-7 10.1016/j.diagmicrobio.2008.09.001 10.1136/bmj.j4008 10.1016/j.jmii.2018.11.004 10.1016/S1579-2129(11)60008-6 10.1378/chest.128.1.172 10.1111/j.1365-2710.2009.01073.x 10.2169/internalmedicine.45.1717 10.1007/s00134-017-4683-6 10.1007/s11596-006-0411-0 10.7326/M14-2385 10.2169/internalmedicine.48.1614 10.1093/jac/dkr096 10.1177/0962280207080643 10.1378/chest.128.5.3398 10.1590/s1677-5538.ibju.2018.03.02 10.1016/s0025-7753(00)71625-3 10.1136/thoraxjnl-2013-204282 10.1136/bmj.g5630 10.1086/498520 10.3390/microorganisms7080270 10.1007/BF03261911 10.1016/j.medcli.2016.02.025 10.1016/j.rceng.2012.12.001 10.1016/S0011-393X(01)89002-0 10.1002/jrsm.1204 10.1016/j.chest.2016.02.635 10.1086/339543 10.1186/1471-2288-13-35 10.1002/jrsm.1278 10.1093/jac/dkr097 10.1007/s10096-005-1347-1 10.1086/511159 10.3760/cma.j.issn.0366-6999.20131635 10.1016/j.arbres.2010.06.014 10.1016/j.rce.2012.09.011 10.1016/S0025-7753(00)71625-3 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1136/thoraxjnl-2019-214054 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central BMJ Journals ProQuest One Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) BMJ Journals Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Academic Middle East (New) MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-3296 |
| EndPage | 1031 |
| ExternalDocumentID | 33723019 10_1136_thoraxjnl_2019_214054 thoraxjnl |
| Genre | Network Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | --- .55 .GJ .VT 08G 0R~ 123 18M 29Q 2WC 354 39C 3O- 4.4 40O 53G 5RE 5VS 6PF 7X7 7~S 88E 8F7 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAYEP ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGTL ACHTP ACMFJ ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C45 CAG CCPQU COF CS3 CXRWF DIK DU5 E3Z EBS EJD F5P FEDTE FYUFA GX1 H13 HAJ HMCUK HVGLF HYE HZ~ IAO IEA IH2 IHR IOF ITC J5H KQ8 L7B M1P N4W N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W8F WH7 X7M YFH YOC YQY ZCG ZGI AAYXX ACQHZ ADGHP AERUA CITATION PHGZM CGR CUY CVF ECM EIF NPM PJZUB PPXIY 3V. 7XB 8FK K9. PKEHL PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-b420t-a852fb24a561564a43b5a6574a4445d5251d6e986a077318191eb2dff9095b9b3 |
| IEDL.DBID | 7X7 |
| ISSN | 0040-6376 1468-3296 |
| IngestDate | Mon Jul 21 11:56:40 EDT 2025 Sat Jul 26 02:32:30 EDT 2025 Mon Jul 21 06:02:08 EDT 2025 Tue Jul 01 02:00:43 EDT 2025 Thu Apr 24 22:54:54 EDT 2025 Thu Apr 24 23:09:37 EDT 2025 Thu Apr 24 22:49:49 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | pneumonia emergency medicine clinical epidemiology respiratory infection |
| Language | English |
| License | Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b420t-a852fb24a561564a43b5a6574a4445d5251d6e986a077318191eb2dff9095b9b3 |
| Notes | Original research ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-4459-8919 |
| PMID | 33723019 |
| PQID | 2573707881 |
| PQPubID | 2041050 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2501849359 proquest_journals_2573707881 pubmed_primary_33723019 crossref_primary_10_1136_thoraxjnl_2019_214054 crossref_citationtrail_10_1136_thoraxjnl_2019_214054 bmj_primary_10_1136_thoraxjnl_2019_214054 bmj_journals_10_1136_thoraxjnl_2019_214054 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-01 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Thorax |
| PublicationTitleAbbrev | Thorax |
| PublicationTitleAlternate | Thorax |
| PublicationYear | 2021 |
| Publisher | BMJ Publishing Group Ltd and British Thoracic Society BMJ Publishing Group LTD |
| Publisher_xml | – name: BMJ Publishing Group Ltd and British Thoracic Society – name: BMJ Publishing Group LTD |
| References | Lin, Lin, Chen (R30) 2007; 30 Dal Negro, Pomari, Larosa (R24) 2001; 62 Rücker, Schwarzer (R20) 2015; 15 Low, File, Eckburg (R32) 2011; 66 Eljaaly, Wali, Basilim (R60) 2019; 54 Torres, Garau, Arvis (R42) 2008; 46 Shea, Reeves, Wells (R11) 2017; 358 Brignardello-Petersen, Bonner, Alexander (R12) 2018; 93 Siquier, Sánchez-Alvarez, García-Mendez (R39) 2006; 57 Mokabberi, Haftbaradaran, Ravakhah (R33) 2010; 35 Rosón, Carratalà, Fernández-Sabé (R57) 2004; 164 Hutton, Catala-Lopez, Moher (R21) 2016; 147 Feldman, White, O'Grady (R25) 2001; 17 Menéndez, Torres, Aspa (R5) 2010; 46 Mandell, Wunderink, Anzueto (R4) 2007; 44 Suppl 2 Jain, Self, Wunderink (R51) 2015; 373 Xu, Xiong, Xu (R46) 2006; 26 Baez-Pravia, Montes-Andujar, Menéndez (R8) 2019; 85 Vetter, Cambronero-Hernandez, Rohlf (R43) 2002; 24 Chou, Shen, Chen (R62) 2019; 52 Portier, Brambilla, Garre (R36) 2005; 24 Stevens, Fletcher, Downey (R55) 2018; 9 Chaimani, Salanti (R14) 2012; 3 López-Véjar, Castellanos-De la Cruz, Meraz-Ortega (R31) 2013; 29 Navarta, Bocklet, Anzorena (R34) 2010; 3 Sun, Sun, Wang (R40) 2014; 127 Cardinal-Fernández, Bajwa, Dominguez-Calvo (R7) 2016; 149 Seki, Higashiyama, Imamura (R38) 2009; 48 Kochanek, Murphy, Xu (R1) 2017 Frank, Liu, Kinasewitz (R26) 2002; 24 Welte, Torres, Nathwani (R3) 2012; 67 García-Perdomo (R16) 2018; 44 Scott (R59) 2016; 76 Cardinal-Fernández, García Gabarrot, Echeverria (R6) 2013; 213 Puhan, Schunemann, Murad (R13) 2014; 349 Lee, Kim, Kim (R28) 2012; 32 Woodhead, Blasi, Ewig (R53) 2011; 17 Suppl 6 Rhodes, Evans, Alhazzani (R9) 2017; 43 Romanelli, Cravarezza, Pozzi (R37) 2002; 14 Hutton, Salanti, Caldwell (R10) 2015; 162 Ortiz-Ruiz, Caballero-Lopez, Friedland (R35) 2002; 34 Krahn, Binder, König (R19) 2013; 13 Salanti, Higgins, Ades (R17) 2008; 17 Morganroth, DiMarco, Anzueto (R50) 2005; 128 Leroy, Saux, Bédos (R29) 2005; 128 Kuzman, Ðaković-Rode, Oremuš (R49) 2005; 17 Spellberg, Talbot, Brass (R61) 2008; 47 Suppl 3 Higgins, Jackson, Barrett (R18) 2012; 3 Tanaseanu, Milutinovic, Calistru (R41) 2009; 9 Zhong, Sun, Zhuo (R48) 2015; 15 Sánchez García, De la Torre, Morales (R56) 2010; 303 Koulenti, Xu, Mok (R58) 2019; 7 Kalbermatter, Bagilet, Diab (R27) 2000; 115 File, Low, Eckburg (R47) 2011; 66 Zervos, Mandell, Vrooman (R45) 2004; 3 Neupane, Richer, Bonner (R15) 2014; 9 Bergallo, Jasovich, Teglia (R23) 2009; 63 Metlay, Waterer, Long (R52) 2019; 200 Yanagihara, Fukuda, Seki (R44) 2006; 45 Anzueto, Niederman, Pearle (R22) 2006; 42 Goring, Gustafson, Liu (R54) 2016; 7 Torres, Peetermans, Viegi (R2) 2013; 68 Torres, Garau, Arvis 2008; 46 Woodhead, Blasi, Ewig 2011; 17 Suppl 6 Lin, Lin, Chen 2007; 30 Bergallo, Jasovich, Teglia 2009; 63 Seki, Higashiyama, Imamura 2009; 48 Feldman, White, O'Grady 2001; 17 Shea, Reeves, Wells 2017; 358 Chaimani, Salanti 2012; 3 File, Low, Eckburg 2011; 66 Krahn, Binder, König 2013; 13 Romanelli, Cravarezza, Pozzi 2002; 14 Sun, Sun, Wang 2014; 127 Puhan, Schunemann, Murad 2014; 349 Koulenti, Xu, Mok 2019; 7 Baez-Pravia, Montes-Andujar, Menéndez 2019; 85 Cardinal-Fernández, Bajwa, Dominguez-Calvo 2016; 149 Torres, Peetermans, Viegi 2013; 68 Anzueto, Niederman, Pearle 2006; 42 Vetter, Cambronero-Hernandez, Rohlf 2002; 24 Salanti, Higgins, Ades 2008; 17 Frank, Liu, Kinasewitz 2002; 24 Lee, Kim, Kim 2012; 32 Sánchez García, De la Torre, Morales 2010; 303 Goring, Gustafson, Liu 2016; 7 Rosón, Carratalà, Fernández-Sabé 2004; 164 Ortiz-Ruiz, Caballero-Lopez, Friedland 2002; 34 García-Perdomo 2018; 44 Mandell, Wunderink, Anzueto 2007; 44 Suppl 2 Jain, Self, Wunderink 2015; 373 Hutton, Catala-Lopez, Moher 2016; 147 Dal Negro, Pomari, Larosa 2001; 62 Metlay, Waterer, Long 2019; 200 López-Véjar, Castellanos-De la Cruz, Meraz-Ortega 2013; 29 Kalbermatter, Bagilet, Diab 2000; 115 Zhong, Sun, Zhuo 2015; 15 Cardinal-Fernández, García Gabarrot, Echeverria 2013; 213 Mokabberi, Haftbaradaran, Ravakhah 2010; 35 Portier, Brambilla, Garre 2005; 24 Spellberg, Talbot, Brass 2008; 47 Suppl 3 Rücker, Schwarzer 2015; 15 Neupane, Richer, Bonner 2014; 9 Leroy, Saux, Bédos 2005; 128 Hutton, Salanti, Caldwell 2015; 162 Brignardello-Petersen, Bonner, Alexander 2018; 93 Tanaseanu, Milutinovic, Calistru 2009; 9 Menéndez, Torres, Aspa 2010; 46 Xu, Xiong, Xu 2006; 26 Scott 2016; 76 Kuzman, Ðaković-Rode, Oremuš 2005; 17 Kochanek, Murphy, Xu 2017 Stevens, Fletcher, Downey 2018; 9 Low, File, Eckburg 2011; 66 Morganroth, DiMarco, Anzueto 2005; 128 Eljaaly, Wali, Basilim 2019; 54 Navarta, Bocklet, Anzorena 2010; 3 Welte, Torres, Nathwani 2012; 67 Zervos, Mandell, Vrooman 2004; 3 Chou, Shen, Chen 2019; 52 Yanagihara, Fukuda, Seki 2006; 45 Higgins, Jackson, Barrett 2012; 3 Rhodes, Evans, Alhazzani 2017; 43 Siquier, Sánchez-Alvarez, García-Mendez 2006; 57 Yanagihara (2021102111000652000_76.10.1020.44) 2006; 45 Chou (2021102111000652000_76.10.1020.62) 2019; 52 Jain (2021102111000652000_76.10.1020.51) 2015; 373 Woodhead (2021102111000652000_76.10.1020.53) 2011; 17 Suppl 6 Rücker (2021102111000652000_76.10.1020.20) 2015; 15 Kuzman (2021102111000652000_76.10.1020.49) 2005; 17 Scott (2021102111000652000_76.10.1020.59) 2016; 76 Goring (2021102111000652000_76.10.1020.54) 2016; 7 Lin (2021102111000652000_76.10.1020.30) 2007; 30 Rhodes (2021102111000652000_76.10.1020.9) 2017; 43 Vetter (2021102111000652000_76.10.1020.43) 2002; 24 Mandell (2021102111000652000_76.10.1020.4) 2007; 44 Suppl 2 Frank (2021102111000652000_76.10.1020.26) 2002; 24 Dal Negro (2021102111000652000_76.10.1020.24) 2001; 62 Cardinal-Fernández (2021102111000652000_76.10.1020.6) 2013; 213 Lee (2021102111000652000_76.10.1020.28) 2012; 32 Welte (2021102111000652000_76.10.1020.3) 2012; 67 Torres (2021102111000652000_76.10.1020.42) 2008; 46 Koulenti (2021102111000652000_76.10.1020.58) 2019; 7 Hutton (2021102111000652000_76.10.1020.21) 2016; 147 Low (2021102111000652000_76.10.1020.32) 2011; 66 Romanelli (2021102111000652000_76.10.1020.37) 2002; 14 Siquier (2021102111000652000_76.10.1020.39) 2006; 57 Seki (2021102111000652000_76.10.1020.38) 2009; 48 Metlay (2021102111000652000_76.10.1020.52) 2019; 200 File (2021102111000652000_76.10.1020.47) 2011; 66 Brignardello-Petersen (2021102111000652000_76.10.1020.12) 2018; 93 Navarta (2021102111000652000_76.10.1020.34) 2010; 3 Salanti (2021102111000652000_76.10.1020.17) 2008; 17 Shea (2021102111000652000_76.10.1020.11) 2017; 358 García-Perdomo (2021102111000652000_76.10.1020.16) 2018; 44 Feldman (2021102111000652000_76.10.1020.25) 2001; 17 Tanaseanu (2021102111000652000_76.10.1020.41) 2009; 9 Stevens (2021102111000652000_76.10.1020.55) 2018; 9 López-Véjar (2021102111000652000_76.10.1020.31) 2013; 29 Menéndez (2021102111000652000_76.10.1020.5) 2010; 46 Hutton (2021102111000652000_76.10.1020.10) 2015; 162 Spellberg (2021102111000652000_76.10.1020.61) 2008; 47 Suppl 3 Rosón (2021102111000652000_76.10.1020.57) 2004; 164 Morganroth (2021102111000652000_76.10.1020.50) 2005; 128 Ortiz-Ruiz (2021102111000652000_76.10.1020.35) 2002; 34 Mokabberi (2021102111000652000_76.10.1020.33) 2010; 35 Leroy (2021102111000652000_76.10.1020.29) 2005; 128 Torres (2021102111000652000_76.10.1020.2) 2013; 68 Krahn (2021102111000652000_76.10.1020.19) 2013; 13 Zhong (2021102111000652000_76.10.1020.48) 2015; 15 Kalbermatter (2021102111000652000_76.10.1020.27) 2000; 115 Portier (2021102111000652000_76.10.1020.36) 2005; 24 Bergallo (2021102111000652000_76.10.1020.23) 2009; 63 Anzueto (2021102111000652000_76.10.1020.22) 2006; 42 Baez-Pravia (2021102111000652000_76.10.1020.8) 2019; 85 Sánchez García (2021102111000652000_76.10.1020.56) 2010; 303 2021102111000652000_76.10.1020.13 Chaimani (2021102111000652000_76.10.1020.14) 2012; 3 Xu (2021102111000652000_76.10.1020.46) 2006; 26 2021102111000652000_76.10.1020.15 Sun (2021102111000652000_76.10.1020.40) 2014; 127 Cardinal-Fernández (2021102111000652000_76.10.1020.7) 2016; 149 Higgins (2021102111000652000_76.10.1020.18) 2012; 3 Zervos (2021102111000652000_76.10.1020.45) 2004; 3 Eljaaly (2021102111000652000_76.10.1020.60) 2019; 54 Kochanek (2021102111000652000_76.10.1020.1) 2017 |
| References_xml | – volume: 76 start-page: 1659 year: 2016 ident: R59 article-title: Ceftaroline Fosamil: a review in complicated skin and soft tissue infections and community-acquired pneumonia publication-title: Drugs doi: 10.1007/s40265-016-0654-4 – volume: 54 start-page: 149 year: 2019 ident: R60 article-title: Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2019.05.023 – volume: 200 start-page: e45 year: 2019 ident: R52 article-title: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic Society and infectious diseases Society of America publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201908-1581ST – volume: 17 start-page: 636 year: 2005 ident: R49 article-title: Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study publication-title: J Chemother doi: 10.1179/joc.2005.17.6.636 – volume: 17 Suppl 6 start-page: E1 year: 2011 ident: R53 article-title: Guidelines for the management of adult lower respiratory tract infections--full version publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2011.03672.x – volume: 67 start-page: 71 year: 2012 ident: R3 article-title: Clinical and economic burden of community-acquired pneumonia among adults in Europe publication-title: Thorax doi: 10.1136/thx.2009.129502 – volume: 85 start-page: 433 year: 2019 ident: R8 article-title: What have we learned from network meta-analyses applied to critical care? publication-title: Minerva Anestesiol doi: 10.23736/S0375-9393.19.13267-1 – volume: 9 year: 2009 ident: R41 article-title: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia publication-title: BMC Pulm Med doi: 10.1186/1471-2466-9-44 – volume: 3 start-page: 161 year: 2012 ident: R14 article-title: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions publication-title: Research Synthesis Methods doi: 10.1002/jrsm.57 – volume: 15 year: 2015 ident: R20 article-title: Ranking treatments in frequentist network meta-analysis works without resampling methods publication-title: BMC Med Res Methodol doi: 10.1186/s12874-015-0060-8 – volume: 164 start-page: 502 year: 2004 ident: R57 article-title: Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia publication-title: Arch Intern Med doi: 10.1001/archinte.164.5.502 – volume: 15 start-page: 161 year: 2015 ident: R48 article-title: Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)71018-7 – volume: 303 start-page: 2260 year: 2010 ident: R56 article-title: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit publication-title: JAMA doi: 10.1001/jama.2010.757 – volume: 3 start-page: 329 year: 2004 ident: R45 article-title: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia publication-title: Treat Respir Med doi: 10.2165/00151829-200403050-00006 – volume: 57 start-page: 536 year: 2006 ident: R39 article-title: Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 Mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki480 – volume: 14 start-page: 609 year: 2002 ident: R37 article-title: Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy publication-title: J Chemother doi: 10.1179/joc.2002.14.6.609 – volume: 29 start-page: 587 year: 2013 ident: R31 article-title: Eficacia del levofloxacino en El tratamiento de neumonía adquirida en La comunidad publication-title: Med Int Mex – volume: 24 start-page: 1770 year: 2002 ident: R43 article-title: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80078-9 – volume: 373 start-page: 415 year: 2015 ident: R51 article-title: Community-Acquired pneumonia requiring hospitalization among U.S. adults publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1500245 – volume: 9 year: 2014 ident: R15 article-title: Network meta-analysis using R: a review of currently available automated packages publication-title: PLoS One doi: 10.1371/journal.pone.0115065 – volume: 3 start-page: 98 year: 2012 ident: R18 article-title: Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies publication-title: Research Synthesis Methods doi: 10.1002/jrsm.1044 – volume: 93 start-page: 36 year: 2018 ident: R12 article-title: Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2017.10.005 – volume: 24 start-page: 1292 year: 2002 ident: R26 article-title: A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80034-0 – volume: 46 start-page: 1499 year: 2008 ident: R42 article-title: Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial publication-title: Clin Infect Dis doi: 10.1086/587519 – volume: 17 start-page: 177 year: 2001 ident: R25 article-title: An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(00)00344-7 – volume: 63 start-page: 52 year: 2009 ident: R23 article-title: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.09.001 – volume: 358 start-page: j4008 year: 2017 ident: R11 article-title: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both publication-title: BMJ doi: 10.1136/bmj.j4008 – volume: 52 start-page: 172 year: 2019 ident: R62 article-title: Recommendations and guidelines for the treatment of pneumonia in Taiwan publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2018.11.004 – volume: 46 start-page: 543 year: 2010 ident: R5 article-title: Community-Acquired pneumonia. new guidelines of the Spanish Society of pulmonology and thoracic surgery (SEPAR) publication-title: Archivos de Bronconeumología doi: 10.1016/S1579-2129(11)60008-6 – volume: 128 start-page: 172 year: 2005 ident: R29 article-title: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors publication-title: Chest doi: 10.1378/chest.128.1.172 – volume: 35 start-page: 195 year: 2010 ident: R33 article-title: Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2009.01073.x – volume: 45 start-page: 995 year: 2006 ident: R44 article-title: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.45.1717 – volume: 43 start-page: 304 year: 2017 ident: R9 article-title: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 publication-title: Intensive Care Med doi: 10.1007/s00134-017-4683-6 – volume: 127 start-page: 1201 year: 2014 ident: R40 article-title: Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors publication-title: Chin Med J – volume: 26 start-page: 421 year: 2006 ident: R46 article-title: Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia publication-title: J Huazhong Univ Sci Technolog Med Sci doi: 10.1007/s11596-006-0411-0 – volume: 162 start-page: 777 year: 2015 ident: R10 article-title: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations publication-title: Ann Intern Med doi: 10.7326/M14-2385 – volume: 48 start-page: 49 year: 2009 ident: R38 article-title: A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.48.1614 – volume: 66 start-page: iii19 year: 2011 ident: R47 article-title: Focus 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr096 – volume: 17 start-page: 279 year: 2008 ident: R17 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res doi: 10.1177/0962280207080643 – volume: 128 start-page: 3398 year: 2005 ident: R50 article-title: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia publication-title: Chest doi: 10.1378/chest.128.5.3398 – volume: 44 start-page: 422 year: 2018 ident: R16 article-title: Network meta-analysis, a new statistical technique at urologists' disposal to improve decision making publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2018.03.02 – volume: 115 start-page: 561 year: 2000 ident: R27 article-title: [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization] publication-title: Med Clin doi: 10.1016/s0025-7753(00)71625-3 – volume: 68 start-page: 1057 year: 2013 ident: R2 article-title: Risk factors for community-acquired pneumonia in adults in Europe: a literature review publication-title: Thorax doi: 10.1136/thoraxjnl-2013-204282 – volume: 47 Suppl 3 start-page: S249 year: 2008 ident: R61 article-title: Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia publication-title: Clin Infect Dis – volume: 349 year: 2014 ident: R13 article-title: A grade Working group approach for rating the quality of treatment effect estimates from network meta-analysis publication-title: BMJ doi: 10.1136/bmj.g5630 – volume: 3 start-page: 97 year: 2010 ident: R34 article-title: Eficacia clínica de Los macrólidos como parte del tratamiento empírico en neumonía de la comunidad que se interna publication-title: Rev Am Med Resp – volume: 42 start-page: 73 year: 2006 ident: R22 article-title: Community-Acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy publication-title: Clin Infect Dis doi: 10.1086/498520 – volume: 7 start-page: 270 year: 2019 ident: R58 article-title: Novel antibiotics for multidrug-resistant gram-positive microorganisms publication-title: Microorganisms doi: 10.3390/microorganisms7080270 – volume: 32 start-page: 569 year: 2012 ident: R28 article-title: High-Dose levofloxacin in community-acquired pneumonia: a randomized, open-label study publication-title: Clin Drug Investig doi: 10.1007/BF03261911 – start-page: 1 year: 2017 ident: R1 article-title: Mortality in the United States, 2016 publication-title: NCHS Data Brief – volume: 147 start-page: 262 year: 2016 ident: R21 article-title: [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA] publication-title: Med Clin doi: 10.1016/j.medcli.2016.02.025 – volume: 213 start-page: 88 year: 2013 ident: R6 article-title: Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae publication-title: Revista Clínica Española doi: 10.1016/j.rceng.2012.12.001 – volume: 62 start-page: 372 year: 2001 ident: R24 article-title: Quantitative assessment of chest radiographs to evaluate the efficacy of ceftazidime versus ceftriaxone in a randomized, double-blind study in adults with community-acquired pneumonia publication-title: Curr Ther Res doi: 10.1016/S0011-393X(01)89002-0 – volume: 7 start-page: 420 year: 2016 ident: R54 article-title: Disconnected by design: Analytic approach in treatment networks having no common comparator publication-title: Res Synth Methods doi: 10.1002/jrsm.1204 – volume: 149 start-page: 1155 year: 2016 ident: R7 article-title: The Presence of Diffuse Alveolar Damage on Open Lung Biopsy Is Associated With Mortality in Patients With Acute Respiratory Distress Syndrome publication-title: Chest doi: 10.1016/j.chest.2016.02.635 – volume: 34 start-page: 1076 year: 2002 ident: R35 article-title: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/339543 – volume: 13 year: 2013 ident: R19 article-title: A graphical tool for locating inconsistency in network meta-analyses publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-13-35 – volume: 9 start-page: 148 year: 2018 ident: R55 article-title: A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence publication-title: Res Synth Methods doi: 10.1002/jrsm.1278 – volume: 30 start-page: 321 year: 2007 ident: R30 article-title: An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia publication-title: Chang Gung Med J – volume: 66 start-page: iii33 year: 2011 ident: R32 article-title: Focus 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr097 – volume: 24 start-page: 367 year: 2005 ident: R36 article-title: Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-005-1347-1 – volume: 44 Suppl 2 start-page: S27 year: 2007 ident: R4 article-title: Infectious diseases Society of America/American thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/511159 – volume: 17 Suppl 6 start-page: E1 year: 2011 article-title: Guidelines for the management of adult lower respiratory tract infections--full version publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2011.03672.x – volume: 213 start-page: 88 year: 2013 article-title: Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae publication-title: Revista Clínica Española doi: 10.1016/j.rceng.2012.12.001 – volume: 128 start-page: 3398 year: 2005 article-title: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia publication-title: Chest doi: 10.1378/chest.128.5.3398 – volume: 47 Suppl 3 start-page: S249 year: 2008 article-title: Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia publication-title: Clin Infect Dis – volume: 3 start-page: 329 year: 2004 article-title: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia publication-title: Treat Respir Med doi: 10.2165/00151829-200403050-00006 – volume: 43 start-page: 304 year: 2017 article-title: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 publication-title: Intensive Care Med doi: 10.1007/s00134-017-4683-6 – volume: 303 start-page: 2260 year: 2010 article-title: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit publication-title: JAMA doi: 10.1001/jama.2010.757 – volume: 149 start-page: 1155 year: 2016 article-title: The Presence of Diffuse Alveolar Damage on Open Lung Biopsy Is Associated With Mortality in Patients With Acute Respiratory Distress Syndrome publication-title: Chest doi: 10.1016/j.chest.2016.02.635 – volume: 147 start-page: 262 year: 2016 article-title: [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA] publication-title: Med Clin doi: 10.1016/j.medcli.2016.02.025 – volume: 54 start-page: 149 year: 2019 article-title: Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2019.05.023 – volume: 373 start-page: 415 year: 2015 article-title: Community-Acquired pneumonia requiring hospitalization among U.S. adults publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1500245 – volume: 52 start-page: 172 year: 2019 article-title: Recommendations and guidelines for the treatment of pneumonia in Taiwan publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2018.11.004 – volume: 62 start-page: 372 year: 2001 article-title: Quantitative assessment of chest radiographs to evaluate the efficacy of ceftazidime versus ceftriaxone in a randomized, double-blind study in adults with community-acquired pneumonia publication-title: Curr Ther Res doi: 10.1016/S0011-393X(01)89002-0 – volume: 15 start-page: 161 year: 2015 article-title: Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)71018-7 – volume: 85 start-page: 433 year: 2019 article-title: What have we learned from network meta-analyses applied to critical care? publication-title: Minerva Anestesiol doi: 10.23736/S0375-9393.19.13267-1 – volume: 13 year: 2013 article-title: A graphical tool for locating inconsistency in network meta-analyses publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-13-35 – volume: 3 start-page: 161 year: 2012 article-title: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions publication-title: Research Synthesis Methods doi: 10.1002/jrsm.57 – volume: 24 start-page: 1292 year: 2002 article-title: A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80034-0 – volume: 46 start-page: 543 year: 2010 article-title: Community-Acquired pneumonia. new guidelines of the Spanish Society of pulmonology and thoracic surgery (SEPAR) publication-title: Archivos de Bronconeumología doi: 10.1016/S1579-2129(11)60008-6 – volume: 34 start-page: 1076 year: 2002 article-title: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/339543 – volume: 349 year: 2014 article-title: A grade Working group approach for rating the quality of treatment effect estimates from network meta-analysis publication-title: BMJ doi: 10.1136/bmj.g5630 – volume: 30 start-page: 321 year: 2007 article-title: An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia publication-title: Chang Gung Med J – volume: 48 start-page: 49 year: 2009 article-title: A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.48.1614 – volume: 24 start-page: 1770 year: 2002 article-title: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80078-9 – volume: 115 start-page: 561 year: 2000 article-title: [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization] publication-title: Med Clin doi: 10.1016/s0025-7753(00)71625-3 – volume: 128 start-page: 172 year: 2005 article-title: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors publication-title: Chest doi: 10.1378/chest.128.1.172 – volume: 15 year: 2015 article-title: Ranking treatments in frequentist network meta-analysis works without resampling methods publication-title: BMC Med Res Methodol doi: 10.1186/s12874-015-0060-8 – volume: 9 year: 2014 article-title: Network meta-analysis using R: a review of currently available automated packages publication-title: PLoS One doi: 10.1371/journal.pone.0115065 – volume: 127 start-page: 1201 year: 2014 article-title: Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors publication-title: Chin Med J – volume: 164 start-page: 502 year: 2004 article-title: Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia publication-title: Arch Intern Med doi: 10.1001/archinte.164.5.502 – volume: 35 start-page: 195 year: 2010 article-title: Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2009.01073.x – volume: 67 start-page: 71 year: 2012 article-title: Clinical and economic burden of community-acquired pneumonia among adults in Europe publication-title: Thorax doi: 10.1136/thx.2009.129502 – volume: 14 start-page: 609 year: 2002 article-title: Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy publication-title: J Chemother doi: 10.1179/joc.2002.14.6.609 – volume: 42 start-page: 73 year: 2006 article-title: Community-Acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy publication-title: Clin Infect Dis doi: 10.1086/498520 – volume: 68 start-page: 1057 year: 2013 article-title: Risk factors for community-acquired pneumonia in adults in Europe: a literature review publication-title: Thorax doi: 10.1136/thoraxjnl-2013-204282 – volume: 66 start-page: iii19 year: 2011 article-title: Focus 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr096 – volume: 358 start-page: j4008 year: 2017 article-title: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both publication-title: BMJ doi: 10.1136/bmj.j4008 – volume: 17 start-page: 177 year: 2001 article-title: An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(00)00344-7 – volume: 32 start-page: 569 year: 2012 article-title: High-Dose levofloxacin in community-acquired pneumonia: a randomized, open-label study publication-title: Clin Drug Investig doi: 10.1007/BF03261911 – volume: 9 year: 2009 article-title: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia publication-title: BMC Pulm Med doi: 10.1186/1471-2466-9-44 – volume: 46 start-page: 1499 year: 2008 article-title: Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial publication-title: Clin Infect Dis doi: 10.1086/587519 – volume: 63 start-page: 52 year: 2009 article-title: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.09.001 – volume: 3 start-page: 97 year: 2010 article-title: Eficacia clínica de Los macrólidos como parte del tratamiento empírico en neumonía de la comunidad que se interna publication-title: Rev Am Med Resp – volume: 76 start-page: 1659 year: 2016 article-title: Ceftaroline Fosamil: a review in complicated skin and soft tissue infections and community-acquired pneumonia publication-title: Drugs doi: 10.1007/s40265-016-0654-4 – volume: 57 start-page: 536 year: 2006 article-title: Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 Mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki480 – volume: 66 start-page: iii33 year: 2011 article-title: Focus 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr097 – volume: 7 start-page: 420 year: 2016 article-title: Disconnected by design: Analytic approach in treatment networks having no common comparator publication-title: Res Synth Methods doi: 10.1002/jrsm.1204 – volume: 162 start-page: 777 year: 2015 article-title: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations publication-title: Ann Intern Med doi: 10.7326/M14-2385 – volume: 7 start-page: 270 year: 2019 article-title: Novel antibiotics for multidrug-resistant gram-positive microorganisms publication-title: Microorganisms doi: 10.3390/microorganisms7080270 – volume: 17 start-page: 636 year: 2005 article-title: Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study publication-title: J Chemother doi: 10.1179/joc.2005.17.6.636 – volume: 44 Suppl 2 start-page: S27 year: 2007 article-title: Infectious diseases Society of America/American thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/511159 – volume: 9 start-page: 148 year: 2018 article-title: A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence publication-title: Res Synth Methods doi: 10.1002/jrsm.1278 – volume: 3 start-page: 98 year: 2012 article-title: Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies publication-title: Research Synthesis Methods doi: 10.1002/jrsm.1044 – volume: 45 start-page: 995 year: 2006 article-title: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.45.1717 – volume: 93 start-page: 36 year: 2018 article-title: Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2017.10.005 – volume: 44 start-page: 422 year: 2018 article-title: Network meta-analysis, a new statistical technique at urologists' disposal to improve decision making publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2018.03.02 – volume: 17 start-page: 279 year: 2008 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res doi: 10.1177/0962280207080643 – volume: 200 start-page: e45 year: 2019 article-title: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic Society and infectious diseases Society of America publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201908-1581ST – volume: 24 start-page: 367 year: 2005 article-title: Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-005-1347-1 – volume: 26 start-page: 421 year: 2006 article-title: Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia publication-title: J Huazhong Univ Sci Technolog Med Sci doi: 10.1007/s11596-006-0411-0 – start-page: 1 year: 2017 article-title: Mortality in the United States, 2016 publication-title: NCHS Data Brief – volume: 29 start-page: 587 year: 2013 article-title: Eficacia del levofloxacino en El tratamiento de neumonía adquirida en La comunidad publication-title: Med Int Mex – volume: 3 start-page: 161 year: 2012 ident: 2021102111000652000_76.10.1020.14 article-title: Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions publication-title: Research Synthesis Methods doi: 10.1002/jrsm.57 – volume: 34 start-page: 1076 year: 2002 ident: 2021102111000652000_76.10.1020.35 article-title: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/339543 – volume: 128 start-page: 3398 year: 2005 ident: 2021102111000652000_76.10.1020.50 article-title: A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia publication-title: Chest doi: 10.1378/chest.128.5.3398 – volume: 13 year: 2013 ident: 2021102111000652000_76.10.1020.19 article-title: A graphical tool for locating inconsistency in network meta-analyses publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-13-35 – volume: 147 start-page: 262 year: 2016 ident: 2021102111000652000_76.10.1020.21 article-title: [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA] publication-title: Med Clin doi: 10.1016/j.medcli.2016.02.025 – volume: 32 start-page: 569 year: 2012 ident: 2021102111000652000_76.10.1020.28 article-title: High-Dose levofloxacin in community-acquired pneumonia: a randomized, open-label study publication-title: Clin Drug Investig doi: 10.1007/BF03261911 – volume: 76 start-page: 1659 year: 2016 ident: 2021102111000652000_76.10.1020.59 article-title: Ceftaroline Fosamil: a review in complicated skin and soft tissue infections and community-acquired pneumonia publication-title: Drugs doi: 10.1007/s40265-016-0654-4 – volume: 17 start-page: 177 year: 2001 ident: 2021102111000652000_76.10.1020.25 article-title: An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia publication-title: Int J Antimicrob Agents doi: 10.1016/S0924-8579(00)00344-7 – volume: 29 start-page: 587 year: 2013 ident: 2021102111000652000_76.10.1020.31 article-title: Eficacia del levofloxacino en El tratamiento de neumonía adquirida en La comunidad publication-title: Med Int Mex – volume: 62 start-page: 372 year: 2001 ident: 2021102111000652000_76.10.1020.24 article-title: Quantitative assessment of chest radiographs to evaluate the efficacy of ceftazidime versus ceftriaxone in a randomized, double-blind study in adults with community-acquired pneumonia publication-title: Curr Ther Res doi: 10.1016/S0011-393X(01)89002-0 – volume: 85 start-page: 433 year: 2019 ident: 2021102111000652000_76.10.1020.8 article-title: What have we learned from network meta-analyses applied to critical care? publication-title: Minerva Anestesiol doi: 10.23736/S0375-9393.19.13267-1 – volume: 66 start-page: iii33 year: 2011 ident: 2021102111000652000_76.10.1020.32 article-title: Focus 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr097 – volume: 54 start-page: 149 year: 2019 ident: 2021102111000652000_76.10.1020.60 article-title: Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2019.05.023 – volume: 68 start-page: 1057 year: 2013 ident: 2021102111000652000_76.10.1020.2 article-title: Risk factors for community-acquired pneumonia in adults in Europe: a literature review publication-title: Thorax doi: 10.1136/thoraxjnl-2013-204282 – volume: 162 start-page: 777 year: 2015 ident: 2021102111000652000_76.10.1020.10 article-title: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations publication-title: Ann Intern Med doi: 10.7326/M14-2385 – volume: 15 start-page: 161 year: 2015 ident: 2021102111000652000_76.10.1020.48 article-title: Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)71018-7 – volume: 9 year: 2009 ident: 2021102111000652000_76.10.1020.41 article-title: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia publication-title: BMC Pulm Med doi: 10.1186/1471-2466-9-44 – volume: 24 start-page: 367 year: 2005 ident: 2021102111000652000_76.10.1020.36 article-title: Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-005-1347-1 – volume: 63 start-page: 52 year: 2009 ident: 2021102111000652000_76.10.1020.23 article-title: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2008.09.001 – volume: 44 Suppl 2 start-page: S27 year: 2007 ident: 2021102111000652000_76.10.1020.4 article-title: Infectious diseases Society of America/American thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults publication-title: Clin Infect Dis doi: 10.1086/511159 – volume: 164 start-page: 502 year: 2004 ident: 2021102111000652000_76.10.1020.57 article-title: Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia publication-title: Arch Intern Med doi: 10.1001/archinte.164.5.502 – volume: 358 start-page: j4008 year: 2017 ident: 2021102111000652000_76.10.1020.11 article-title: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both publication-title: BMJ doi: 10.1136/bmj.j4008 – volume: 7 start-page: 420 year: 2016 ident: 2021102111000652000_76.10.1020.54 article-title: Disconnected by design: Analytic approach in treatment networks having no common comparator publication-title: Res Synth Methods doi: 10.1002/jrsm.1204 – volume: 373 start-page: 415 year: 2015 ident: 2021102111000652000_76.10.1020.51 article-title: Community-Acquired pneumonia requiring hospitalization among U.S. adults publication-title: N Engl J Med Overseas Ed doi: 10.1056/NEJMoa1500245 – volume: 7 start-page: 270 year: 2019 ident: 2021102111000652000_76.10.1020.58 article-title: Novel antibiotics for multidrug-resistant gram-positive microorganisms publication-title: Microorganisms doi: 10.3390/microorganisms7080270 – volume: 3 start-page: 329 year: 2004 ident: 2021102111000652000_76.10.1020.45 article-title: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia publication-title: Treat Respir Med doi: 10.2165/00151829-200403050-00006 – volume: 3 start-page: 98 year: 2012 ident: 2021102111000652000_76.10.1020.18 article-title: Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies publication-title: Research Synthesis Methods doi: 10.1002/jrsm.1044 – volume: 42 start-page: 73 year: 2006 ident: 2021102111000652000_76.10.1020.22 article-title: Community-Acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy publication-title: Clin Infect Dis doi: 10.1086/498520 – volume: 48 start-page: 49 year: 2009 ident: 2021102111000652000_76.10.1020.38 article-title: A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.48.1614 – volume: 47 Suppl 3 start-page: S249 year: 2008 ident: 2021102111000652000_76.10.1020.61 article-title: Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia publication-title: Clin Infect Dis – volume: 9 start-page: 148 year: 2018 ident: 2021102111000652000_76.10.1020.55 article-title: A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence publication-title: Res Synth Methods doi: 10.1002/jrsm.1278 – volume: 303 start-page: 2260 year: 2010 ident: 2021102111000652000_76.10.1020.56 article-title: Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit publication-title: JAMA doi: 10.1001/jama.2010.757 – volume: 26 start-page: 421 year: 2006 ident: 2021102111000652000_76.10.1020.46 article-title: Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia publication-title: J Huazhong Univ Sci Technolog Med Sci doi: 10.1007/s11596-006-0411-0 – volume: 127 start-page: 1201 year: 2014 ident: 2021102111000652000_76.10.1020.40 article-title: Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors publication-title: Chin Med J doi: 10.3760/cma.j.issn.0366-6999.20131635 – start-page: 1 year: 2017 ident: 2021102111000652000_76.10.1020.1 article-title: Mortality in the United States, 2016 publication-title: NCHS Data Brief – volume: 46 start-page: 543 year: 2010 ident: 2021102111000652000_76.10.1020.5 article-title: Community-Acquired pneumonia. new guidelines of the Spanish Society of pulmonology and thoracic surgery (SEPAR) publication-title: Archivos de Bronconeumología doi: 10.1016/j.arbres.2010.06.014 – volume: 17 start-page: 279 year: 2008 ident: 2021102111000652000_76.10.1020.17 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res doi: 10.1177/0962280207080643 – volume: 45 start-page: 995 year: 2006 ident: 2021102111000652000_76.10.1020.44 article-title: Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia publication-title: Intern Med doi: 10.2169/internalmedicine.45.1717 – volume: 213 start-page: 88 year: 2013 ident: 2021102111000652000_76.10.1020.6 article-title: Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae publication-title: Revista Clínica Española doi: 10.1016/j.rce.2012.09.011 – ident: 2021102111000652000_76.10.1020.13 doi: 10.1136/bmj.g5630 – volume: 15 year: 2015 ident: 2021102111000652000_76.10.1020.20 article-title: Ranking treatments in frequentist network meta-analysis works without resampling methods publication-title: BMC Med Res Methodol doi: 10.1186/s12874-015-0060-8 – volume: 30 start-page: 321 year: 2007 ident: 2021102111000652000_76.10.1020.30 article-title: An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia publication-title: Chang Gung Med J – volume: 200 start-page: e45 year: 2019 ident: 2021102111000652000_76.10.1020.52 article-title: Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic Society and infectious diseases Society of America publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201908-1581ST – volume: 149 start-page: 1155 year: 2016 ident: 2021102111000652000_76.10.1020.7 article-title: The Presence of Diffuse Alveolar Damage on Open Lung Biopsy Is Associated With Mortality in Patients With Acute Respiratory Distress Syndrome publication-title: Chest doi: 10.1016/j.chest.2016.02.635 – volume: 3 start-page: 97 year: 2010 ident: 2021102111000652000_76.10.1020.34 article-title: Eficacia clínica de Los macrólidos como parte del tratamiento empírico en neumonía de la comunidad que se interna publication-title: Rev Am Med Resp – volume: 17 start-page: 636 year: 2005 ident: 2021102111000652000_76.10.1020.49 article-title: Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study publication-title: J Chemother doi: 10.1179/joc.2005.17.6.636 – volume: 14 start-page: 609 year: 2002 ident: 2021102111000652000_76.10.1020.37 article-title: Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy publication-title: J Chemother doi: 10.1179/joc.2002.14.6.609 – volume: 46 start-page: 1499 year: 2008 ident: 2021102111000652000_76.10.1020.42 article-title: Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial publication-title: Clin Infect Dis doi: 10.1086/587519 – volume: 43 start-page: 304 year: 2017 ident: 2021102111000652000_76.10.1020.9 article-title: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 publication-title: Intensive Care Med doi: 10.1007/s00134-017-4683-6 – volume: 57 start-page: 536 year: 2006 ident: 2021102111000652000_76.10.1020.39 article-title: Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 Mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki480 – volume: 24 start-page: 1292 year: 2002 ident: 2021102111000652000_76.10.1020.26 article-title: A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80034-0 – volume: 17 Suppl 6 start-page: E1 year: 2011 ident: 2021102111000652000_76.10.1020.53 article-title: Guidelines for the management of adult lower respiratory tract infections--full version publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2011.03672.x – volume: 52 start-page: 172 year: 2019 ident: 2021102111000652000_76.10.1020.62 article-title: Recommendations and guidelines for the treatment of pneumonia in Taiwan publication-title: J Microbiol Immunol Infect doi: 10.1016/j.jmii.2018.11.004 – volume: 35 start-page: 195 year: 2010 ident: 2021102111000652000_76.10.1020.33 article-title: Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2009.01073.x – volume: 24 start-page: 1770 year: 2002 ident: 2021102111000652000_76.10.1020.43 article-title: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80078-9 – volume: 115 start-page: 561 year: 2000 ident: 2021102111000652000_76.10.1020.27 article-title: [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization] publication-title: Med Clin doi: 10.1016/S0025-7753(00)71625-3 – volume: 44 start-page: 422 year: 2018 ident: 2021102111000652000_76.10.1020.16 article-title: Network meta-analysis, a new statistical technique at urologists' disposal to improve decision making publication-title: Int Braz J Urol doi: 10.1590/s1677-5538.ibju.2018.03.02 – volume: 66 start-page: iii19 year: 2011 ident: 2021102111000652000_76.10.1020.47 article-title: Focus 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr096 – volume: 67 start-page: 71 year: 2012 ident: 2021102111000652000_76.10.1020.3 article-title: Clinical and economic burden of community-acquired pneumonia among adults in Europe publication-title: Thorax doi: 10.1136/thx.2009.129502 – volume: 93 start-page: 36 year: 2018 ident: 2021102111000652000_76.10.1020.12 article-title: Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2017.10.005 – ident: 2021102111000652000_76.10.1020.15 doi: 10.1371/journal.pone.0115065 – volume: 128 start-page: 172 year: 2005 ident: 2021102111000652000_76.10.1020.29 article-title: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors publication-title: Chest doi: 10.1378/chest.128.1.172 |
| SSID | ssj0008117 |
| Score | 2.4265656 |
| SecondaryResourceType | review_article |
| Snippet | ObjectiveThe main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in... The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1)... |
| SourceID | proquest pubmed crossref bmj |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1020 |
| SubjectTerms | Adolescent Adult Anti-Bacterial Agents - therapeutic use Antibiotics Bias clinical epidemiology Community-Acquired Infections - drug therapy emergency medicine Humans Medical Subject Headings-MeSH Meta-analysis Mortality Patients Pneumonia Pneumonia - drug therapy Respiratory infection Systematic review |
| Title | Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis |
| URI | https://thorax.bmj.com/content/76/10/1020.full https://thorax.bmj.com/content/early/2021/03/15/thoraxjnl-2019-214054.full https://www.ncbi.nlm.nih.gov/pubmed/33723019 https://www.proquest.com/docview/2573707881 https://www.proquest.com/docview/2501849359 |
| Volume | 76 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB7ygNJLadLXtklQoZcU1Ozaeti9lCRsCIGEEhrYm9HL1CHr3Xa9tP33nbG1XnpokpuxJRmNRtJ80sw3AB90Zr1U2nFtcBiEyxQ3uFPzrCyVkggpfKAb3csrdX4jLiZyEg_cFtGtcrUmtgu1nzk6Iz9C1UqJmSYbfZn_4JQ1im5XYwqNTdgm6jJy6dKTHnANKYhy5TWncCbFCJ5Rqo6a7yjh37f1HarJKOcJ4gzKCLBpp7f_7lD_MTvb7efsOTyLdiM77gZ6BzZCvQtPLuPN-Av4NZ7OK1zTGEqqstWM2JcZGqTMdREgzR9uHHn9Bs_mdVhidyrDqpq1BBws0qsuPjPD1uTOrAtswTY9vq87j3E2DY3hJpKZvISbs_G303MekypwK5Jhw00mk9ImwqDhJJUwIrXSKKnxSQjpJdo7XoU8U2aoNU54xHMIvn1Z5miM2dymr2CrntXhDTCRee2Mcw4xk0BDxeSIfhJd6tKGxOZhAB9RnEWcFIuixRupKnrZFyT7opP9AA6p8Lzj2HiorFiNUOEilTll1Lh7qNqnvtoj_7O3Gv51L9aKOID3_WeclHTTYuowW1KZIao5BT0P4HWnNv0f01Qj7Bvlb-9v_B08Tch9pvUb3IOt5ucy7KP909iDVskPYPtkfPX1-i-0ZgQg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9tnQS8IL4pDDASPIBk1jqOnSAhxEenjq0VQpu0t-CviExrWmiqsX-Kv5Fz4qTiAcbL3qLEdpS78_l-uS-AZzLRNhbSUKmQDdwkgio8qWmS50LECCms8x7dyVSMj_in4_h4A361uTA-rLLVibWitnPj_5HvoGhFvjJNMny7-E591yjvXW1baDRise_OzxCyLd_sfUT-Pmdsd3T4YUxDVwGqORtUVCUxyzXjCi2HWHDFIx0rEUu84jy2MR74Vrg0EWogJUo8AhpEnzbPU7RGdKojXHcTtniEUKYHW-9H089fOt3v0zbbOD2BezfkDA0jsVN9Q57-PClPUTCHKWWIbHwPgk09O_nzTPyLoVsfeLs34HqwVMm7RrRuwoYrb8GVSfDF34az0WxRoBYlyJtCF3Nf75mgCUxMk3NSnVNlfJyxs2RRuhUSsFCkKEld8oOEgq7L10SRdTlp0qTS4JoW75dNjDqZuUpRFcqn3IGjSyH4XeiV89LdB8ITK40yxiBK42gaqRTxFpO5zLVjOnV9eInkzMI2XGY1wolE1tE-87TPGtr34YUfvGiqelw0lrccykwonu57eJxeNO1VN-0_37Pdsn_9FWvR78PT7jGqAe_bUaWbr_yYAW4sn2bdh3uN2HRvjCKJQHOYPvj34k_g6vhwcpAd7E33H8I15oN36qjFbehVP1buEVpflX4cRJ7A18veZb8Bi2k-qw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD60FYovYr2utjqCPiiMu0nmkgiliO3SWlt8sLBvcW7BlG52dbPU_jV_nWeSSRYftL70LSQzE3IuM-fLuQG8lKm2XEhDpUI2MJMKqvCkpmlRCMERUljnPbonp-LwjH2c8Mka_OpyYXxYZbcnNhu1nRn_j3yIopX4yjRpNCxCWMTn_fHe_Dv1HaS8p7Vrp9GKyLG7ukT4ttg92kdev4rj8cGXD4c0dBigmsWjmqqUx4WOmUIrggumWKK5ElziFWPccjz8rXBZKtRISpR-BDeIRG1RZGiZ6EwnuO463JIJj7yOyUkP9kY-gbOL2BOoxSF7KErEsP6G3P15Xl2giEYZjRHj-G4E63p6_ufp-BeTtzn6xnfhTrBZyftWyLZgzVX3YPMkeOXvw-XBdF7ifkqQS6UuZ77yM0FjmJg2-6S-osr4iGNnybxySyRfqUhZkab4BwmlXRfviCKrwtKkTarBNS3er9podTJ1taIqFFJ5AGc3Qu6HsFHNKvcYCEutNMoYg3iNoZGkMkResSxkoV2sMzeAN0jOPCjkIm-wTiLynva5p33e0n4Ar_3geVvf47qxrONQbkIZdd_N4-K6aW_7af_5nu2O_auvWCnBAF70j3FD8F4eVbnZ0o8ZoYr5hOsBPGrFpn9jkkiEnFH25N-LP4dN1K3809Hp8VO4HfsoniZ8cRs26h9Lt4NmWK2fNfJO4OtNK9hvAwlBew |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Empiric+antibiotics+for+community-acquired+pneumonia+in+adult+patients%3A+a+systematic+review+and+a+network+meta-analysis&rft.jtitle=Thorax&rft.au=Montes-Andujar%2C+Lara&rft.au=Tinoco%2C+Elena&rft.au=Baez-Pravia%2C+Orville&rft.au=Martin-Saborido%2C+Carlos&rft.date=2021-10-01&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136%2Fthoraxjnl-2019-214054&rft_id=info%3Apmid%2F33723019&rft.externalDBID=thorax&rft.externalDocID=thoraxjnl |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-6376&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-6376&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-6376&client=summon |